Business Description
Kairos Pharma Ltd. is a Los Angeles-based clinical-stage company focused on developing new treatments for cancer, including prostate, lung, breast cancer, and glioblastoma. The company's pipeline includes several drug candidates that work by helping the body's immune system recognize and fight tumors, as well as therapies that directly target cancer cells. One of its most advanced programs is an antibody treatment for prostate cancer patients who have stopped responding to standard hormone-based therapies, currently in Phase 2 clinical trials. Founded in 2013, the company was previously known as NanoGB13 Inc. before rebranding in 2016.
